We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Teva Challenges Shire's Adderall XR Patent

Law360 (February 23, 2005, 12:00 AM EST) -- Israeli generics maker Teva Pharmaceuticals has initiated a challenge against the patent rights to U.K. drug maker Shire Pharmaceuticals Group PLC’s blockbuster anti-hyperactivity treatment Adderall XR.

Shire said Tuesday it had received a Paragraph IV Notice letter from Teva Pharmaceuticals USA Inc., advising of the filing of an abbreviated new drug application (ANDA) for its amphetamine combination product, a generic version of Shire's mixed amphetamine salts product, Adderall XR.

Shire received previously Paragraph IV Notice letters from Barr Laboratories Inc., Impax Laboratories Inc. and Colony Pharmaceuticals...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.